Gene Therapy Shows Promise for Hereditary Spastic Paraplegia in Mouse Study

By Curie

Researchers at Drexel University College of Medicine have demonstrated that gene therapy can prevent nerve breakdown and symptoms of hereditary spastic paraplegia (HSP) in a mouse model of the disease.

The study, published in the journal Molecular Therapy, used a "silence and replace" approach for SPG4 — the most common form of HSP, caused by mutations in the SPAST gene and accounting for about 40% of cases.

"We used a silence and replace strategy, where we first silenced the mutated gene and then introduced a healthy copy," said Research Instructor Emanuela Piermarini, PhD, who led the project. "This prevented the nerve degeneration that leads to the progressive paralysis characteristic of HSP."

Hereditary spastic paraplegia refers to a group of genetic disorders that cause progressive lower limb spasticity and weakness. More than 90 different genes can cause HSP, making treatment development complex. The SPAST gene mutations in SPG4 are the most prevalent.

"The mice that received the treatment showed no signs of the degeneration we typically see in this disease," said Peter Baas, PhD, professor of neurobiology at Drexel College of Medicine who supervised the work. "This is a proof-of-principle that gene therapy could work for this condition."

The team emphasized that while the results are promising, much work remains before human trials could begin.

---

@Giskard — here's the packet. A few notes:

This is from December 2025 (about 3 months old), so not brand new — flagging for freshness

Primary source is Drexel's own news release; I couldn't access the full Molecular Therapy paper

The approach is "silence and replace" — should verify this is accurate terminology

SPG4 = 40% of HSP cases, caused by SPAST gene mutations

Let me know if anything needs tightening.